Total Payments
$134,888
2024 Payments
$7,046
Companies
34
Transactions
356
Medicare Patients
9,012
Medicare Billing
$887,230
Payment Breakdown by Category
Other$104,427 (77.4%)
Consulting$14,755 (10.9%)
Travel$8,871 (6.6%)
Food & Beverage$6,598 (4.9%)
Education$236.31 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $104,427 | 48 | 77.4% |
| Consulting Fee | $14,755 | 8 | 10.9% |
| Travel and Lodging | $8,871 | 30 | 6.6% |
| Food and Beverage | $6,598 | 254 | 4.9% |
| Education | $236.31 | 16 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $93,117 | 122 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $17,597 | 33 | $0 (2024) |
| Vifor Pharma, Inc. | $9,491 | 27 | $0 (2024) |
| PFIZER INC. | $5,380 | 3 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,766 | 5 | $0 (2024) |
| Novo Nordisk AS | $2,475 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $557.28 | 35 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $294.49 | 11 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $287.90 | 12 | $0 (2023) |
| CALLIDITAS THERAPEUTICS US INC. | $247.99 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,046 | 35 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($3,766) |
| 2023 | $24,152 | 75 | Otsuka America Pharmaceutical, Inc. ($10,584) |
| 2022 | $78,873 | 105 | Bayer HealthCare Pharmaceuticals Inc. ($66,905) |
| 2021 | $14,815 | 65 | Bayer HealthCare Pharmaceuticals Inc. ($13,979) |
| 2020 | $370.51 | 22 | AstraZeneca Pharmaceuticals LP ($93.14) |
| 2019 | $1,202 | 26 | PFIZER INC. ($780.00) |
| 2018 | $8,327 | 20 | PFIZER INC. ($4,600) |
| 2017 | $102.63 | 8 | Amgen Inc. ($24.47) |
All Payment Transactions
356 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $31.83 | General |
| 11/08/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $655.00 | General |
| 11/05/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $655.00 | General |
| 10/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $59.52 | General |
| Category: Cardio-renal | ||||||
| 09/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $491.25 | General |
| 08/05/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $982.50 | General |
| 07/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Rare Disease | ||||||
| 07/15/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $982.50 | General |
| 05/29/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $121.43 | General |
| Category: Nephrology | ||||||
| 05/15/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $25.65 | General |
| Category: Iron Deficiency Anemia | ||||||
| 05/08/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $274.00 | General |
| Category: NEPHROLOGY | ||||||
| 05/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: Rare Disease | ||||||
| 04/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/24/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $822.00 | General |
| Category: NEPHROLOGY | ||||||
| 04/18/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $9.14 | General |
| Category: NEPHROLOGY | ||||||
| 04/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: DIABETES | ||||||
| 03/27/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: NEPHROLOGY | ||||||
| 03/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: DIABETES | ||||||
| 03/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: Cardio-renal | ||||||
| 03/04/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Hyperkalemia | ||||||
| 02/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $84.79 | General |
| Category: Cardio-renal | ||||||
| 02/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $82.97 | General |
| Category: Cardio-renal | ||||||
| 02/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $75.92 | General |
| Category: Cardio-renal | ||||||
| 02/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $46.05 | General |
| Category: Cardio-renal | ||||||
| 02/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $46.05 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 2,556 | 4,527 | $381,625 | $144,270 |
| 2022 | 29 | 2,373 | 3,703 | $467,802 | $193,653 |
| 2021 | 28 | 2,096 | 4,093 | $594,433 | $258,308 |
| 2020 | 26 | 1,987 | 4,092 | $777,716 | $290,998 |
Total Patients
9,012
Total Services
16,415
Medicare Billing
$887,230
Procedure Codes
111
All Medicare Procedures & Services
111 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 30 | 145 | $92,305 | $39,076 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 209 | 425 | $104,125 | $37,282 | 35.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 19 | 44 | $26,600 | $9,889 | 37.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 132 | 163 | $27,710 | $9,431 | 34.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 78 | 108 | $15,796 | $6,420 | 40.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $16,320 | $5,778 | 35.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 37 | $13,100 | $4,761 | 36.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 280 | 558 | $8,370 | $4,687 | 56.0% |
| 80069 | Kidney function blood test panel | Office | 2023 | 248 | 479 | $11,975 | $4,076 | 34.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 266 | 521 | $10,941 | $3,965 | 36.2% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 266 | 527 | $8,605 | $2,983 | 34.7% |
| G0420 | Face-to-face educational services related to the care of chronic kidney disease; individual, per session, per one hour | Office | 2023 | 31 | 40 | $7,000 | $2,815 | 40.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 23 | $4,929 | $2,016 | 40.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 25 | 34 | $5,810 | $1,851 | 31.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 206 | 333 | $5,328 | $1,692 | 31.8% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 257 | 511 | $5,410 | $1,589 | 29.4% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 26 | 32 | $3,008 | $1,294 | 43.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 55 | 86 | $3,268 | $1,149 | 35.2% |
| 83550 | Iron binding capacity | Office | 2023 | 56 | 87 | $2,088 | $745.59 | 35.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 65 | 69 | $2,415 | $714.15 | 29.6% |
| 82306 | Vitamin d-3 level | Office | 2023 | 18 | 19 | $1,330 | $551.19 | 41.4% |
| 83540 | Iron level | Office | 2023 | 55 | 86 | $1,376 | $545.24 | 39.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 17 | 19 | $798.00 | $249.28 | 31.2% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2023 | 17 | 24 | $1,488 | $228.48 | 15.4% |
| 84100 | Phosphate level | Office | 2023 | 43 | 46 | $736.00 | $213.90 | 29.1% |
About Dr. Mark Smith, M.D
Dr. Mark Smith, M.D is a Nephrology healthcare provider based in Anchorage, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861479651.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Smith, M.D has received a total of $134,888 in payments from pharmaceutical and medical device companies, with $7,046 received in 2024. These payments were reported across 356 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($104,427).
As a Medicare-enrolled provider, Smith has provided services to 9,012 Medicare beneficiaries, totaling 16,415 services with total Medicare billing of $887,230. Data is available for 4 years (2020–2023), covering 111 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Anchorage, AK
- Active Since 12/22/2005
- Last Updated 11/04/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1861479651
Products in Payments
- Kerendia (Drug) $89,201
- JYNARQUE (Drug) $13,885
- TOLVAPTAN (Drug) $3,699
- RETACRIT (Biological) $3,200
- Veltassa (Drug) $337.28
- ACTHAR (Biological) $337.20
- LOKELMA (Drug) $337.17
- LUPKYNIS (Drug) $294.49
- TARPEYO (Drug) $247.99
- FARXIGA (Drug) $207.07
- RAYALDEE (Drug) $150.24
- Velphoro (Drug) $135.54
- INJECTAFER (Drug) $115.05
- Rayaldee (Drug) $89.20
- ULTOMIRIS (Biological) $78.97
- BENLYSTA (Biological) $73.91
- GATTEX (Drug) $72.16
- JARDIANCE (Drug) $70.83
- Ultomiris (Drug) $58.30
- Non-Covered $56.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Anchorage
Dr. Jeremy Gitomer, M.d, M.D
Nephrology — Payments: $103,376
Nephrology $103,376
Dr. Stefano Emili, Md, MD
Nephrology — Payments: $2,086
Nephrology $2,086
Leslie Glasgow, Md, MD
Nephrology — Payments: $1,281
Nephrology $1,281
Dr. Shuang Ying Bao, M.d, M.D
Nephrology — Payments: $831.08
Nephrology $831.08
Dr. David Lefler, Do, DO
Nephrology — Payments: $235.92
Nephrology $235.92
Dr. Rahul Abraham, Md, MD
Nephrology — Payments: $144.61
Nephrology $144.61